Nanexa investigates PharmaShell® in a new animal study

Uppsala 9th Oct 2017

 

Nanexa investigates PharmaShell® in a new animal study

Based on the good results from the PharmaShell® animal study conducted during the third quarter of 2017, Nanexa has decided to conduct another animal study. The new study, which has just started, will continue to study the depot effect of PharmaShell®, but under significantly longer duration than the previous study. The study is conducted at the Charles River Laboratory’s pre-clinical unit in Scotland.

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.